National Institutes of Health appeared to be the Corporate Investor, which was created in 1887. The leading representative office of defined Corporate Investor is situated in the Bethesda. The venture was found in North America in United States.
Besides, a startup needs to be aged 16-20 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical, Medical Device. Among the most popular portfolio startups of the fund, we may highlight 23andMe, Neurotrack, Second Sight. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.
The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2016. Considering the real fund results, this Corporate Investor is 31 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from National Institutes of Health is 1-5 millions dollars. Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is constantly included in 13-24 deals per year. Opposing the other organizations, this National Institutes of Health works on 18 percentage points less the average amount of lead investments.
The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the National Institutes of Health, startups are often financed by U.S. Department of Defense, New Enterprise Associates, 5AM Ventures. The meaningful sponsors for the fund in investment in the same round are National Science Foundation, National Institute of Allergy and Infectious Diseases, Small Business Innovation Research. In the next rounds fund is usually obtained by U.S. Department of Defense, Golden Angels Investors, Wisconsin Investment Partners.
Related Funds
| Fund Name | Location |
| Alinea Capital | Norway, Oslo |
| Asia Green Fund | Beijing, Beijing Shi, China |
| Bharti Soft Bank | Belmont, Massachusetts, United States |
| Cabify | Community of Madrid, Madrid, Spain |
| Chunshan Pujiang | China, Shanghai |
| edLABS | - |
| EMBL Ventures | Baden-Wurttemberg, Germany, Heidelberg |
| Gruppo Campari | New York, New York, United States |
| Halley Valley Venture | - |
| JTBC | California, Los Angeles, United States |
| Memorial Hermann Hospital | Houston, Texas, United States |
| Parkland Fuel Corporation | Alberta, Canada, Red Deer |
| TQS Advisors | - |
| Uncle Sam Loves Me, LLC | California, San Francisco, United States |
| WSB Holding | - |
| Yinji Chuangtou | China, Jiangsu, Suzhou |
| Zimmerman Ventures | Milwaukee, United States, Wisconsin |
– CytoAgents was awarded a $2 million National Institutes of Health (NIH) grant, the second NIH grant in a year.
– The funding will accelerate the development of its lead drug candidate, GP1681, an investigational new drug that targets hypercytokinemia, more commonly known as “cytokine storm.”
– Scientific consensus is building that overwhelming inflammation and severe illness is triggered by a phenomenon known as cytokine storm, a severe form of cytokine release syndrome when an excessive immune response attacks the body.
– CytoAgents mission is to develop a broadly accessible treatment for multiple indications of high unmet need of cytokine storm, including for Cytokine Release Syndrome (CRS) in CAR T-cell therapy and in COVID-19 patients.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 